Sign In
1 Nov 2011 17:03
For immediate release | 1 November 2011 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR dealing: LTIP
Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that on 1 November 2011 the Remuneration Committee granted the following conditional nil cost share awards at a price of 370 pence per 0.2 pence Ordinary Share (the closing share price on 31 October 2011) to the Executive Directors and PDMRs of the Company under the Abcam plc Long-Term Incentive Plan (the "LTIP"):
Name | Number of Ordinary Shares subject to the LTIP Award | |
Executive Directors | Jonathan Milner | 82,625 |
Jim Warwick | 61,543 | |
Jeff Iliffe | 70,192 | |
PDMRs | Mark Bushfield | 28,511 |
Jane Cooke | 9,306 | |
Philippe Cotrel | 28,511 | |
Ed Ralph | 13,192 |
The shares subject to these LTIP awards will be released in three years' time subject to continued employment and subject to the satisfaction of certain specific performance conditions based on: the Company's comparative total shareholder return performance against a comparator group of companies; and growth in earnings per share.
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer www.abcamplc.com | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser | |
James Black - Corporate Broking | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 325 staff across its six operating companies.
Abcam now has an online catalogue of over 80,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.
Follow the stocks
